Repligen Opens New Innovation Center in the Netherlands
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 17 2026
0mins
Source: Newsfilter
Repligen Corp's stock fell 9.22% as it crossed below the 20-day SMA amid mixed market conditions, with the Nasdaq-100 slightly up and the S&P 500 down.
The company has inaugurated its new Repligen Training & Innovation Center in Breda, Netherlands, aimed at enhancing customer experience and technical capabilities in the biopharmaceutical sector. This marks Repligen's third center globally, following locations in Waltham and Tokyo, and reflects the company's commitment to expanding its market presence and improving customer support. CEO Olivier Loeillot emphasized that this investment demonstrates Repligen's dedication to meeting growing market demand, particularly in the Asia-Pacific region and the U.S.
This strategic move is expected to strengthen Repligen's position in the biopharmaceutical industry by providing advanced training and support, potentially leading to increased collaboration with biopharmaceutical companies and long-term growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RGEN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RGEN
Wall Street analysts forecast RGEN stock price to rise
12 Analyst Rating
9 Buy
3 Hold
0 Sell
Strong Buy
Current: 113.370
Low
165.00
Averages
189.00
High
207.00
Current: 113.370
Low
165.00
Averages
189.00
High
207.00
About RGEN
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its franchises include filtration, chromatography, process analytics and proteins. Its filtration franchise includes product offering covering upstream and downstream technologies. Its filtration products include XCell Alternating Tangential Flow (ATF) Cell Retention Systems, Flat Sheet Cassettes, Hollow Fiber Consumables, Tangential Flow Filtration Systems and Fluid Management. Its chromatography franchise includes products used in downstream purification, development, manufacturing and quality control of biological drugs. Its chromatography franchise includes OPUS Pre-Packed Columns, KRM Chromatography Systems and other additional chromatography products. Its process analytics include Downstream process analytical technology (PAT) and Upstream PAT. Its Proteins include Protein A Affinity Ligands, AVIPure Resins for New Modalities and Growth Factors.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Repligen to Participate in William Blair Growth Stock Conference in Chicago
- Conference Participation: Repligen Corporation will participate in the 46th Annual Growth Stock Conference hosted by William Blair in Chicago on June 3, where CEO Olivier Loeillot will present a company overview at 10:40 a.m., showcasing its leadership in bioprocessing technology.
- Live Webcast: The presentation will be accessible via Repligen's Investor Relations website, with a replay available for a limited time post-event, ensuring that investors unable to attend can still access critical information.
- Company Background: Repligen is a global leader in life sciences focused on developing and commercializing innovative bioprocessing technologies that enhance the efficiency of biological drug manufacturing, serving biopharmaceutical developers and contract development manufacturing organizations worldwide.
- Global Presence: Headquartered in Waltham, Massachusetts, Repligen has its primary manufacturing sites in the U.S., with additional key facilities in Estonia, Germany, Ireland, the Netherlands, and Sweden, demonstrating its extensive influence in the global market.
See More
Repligen Releases 2025 Corporate Sustainability Report
- Renewable Energy Commitment: Repligen maintains 100% renewable electricity across its U.S. and European manufacturing operations, demonstrating a strong commitment to environmental sustainability that enhances its competitive position in the biopharmaceutical industry.
- Double Materiality Assessment: The company completed its first enterprise-level Double Materiality Assessment aligned with European Sustainability Reporting Standards (ESRS), which not only improved prioritization of material topics but also enhanced regulatory readiness, ensuring compliance with evolving regulations.
- Governance Structure Enhancement: By expanding sustainability oversight to the Audit Committee, Repligen has reinforced governance rigor and data integrity, ensuring alignment with stakeholder expectations, thereby increasing the company's transparency and trustworthiness.
- Water Resource Management Improvement: The company achieved a 14% year-over-year reduction in global water withdrawals, reflecting its commitment to environmental protection and establishing a positive corporate image in the sustainability arena.
See More
April PPI Report Triggers Decline in Healthcare Stocks
- PPI Acceleration Impact: The April PPI report showed a 6% annual increase, with service-sector prices rising at the fastest pace in four years, creating dual pressures on the healthcare sector, increasing operating costs and potentially impacting profitability.
- Cost Pressure: Monthly service-sector inflation rose by 1.2%, significantly increasing operating costs for hospital systems and providers, which may weaken their profitability and affect future investment decisions.
- Regulatory Intervention Risk: As inflation becomes a political focal point, drug companies, due to their visible pricing power, are primary targets for regulatory intervention, which could suppress industry profits.
- Market Overreaction: Despite healthcare stocks like Repligen and AdaptHealth falling by 3.2% and 3.6% respectively, the market's overreaction may present investors with good opportunities to buy high-quality stocks.
See More
Repligen Q1 2026 Earnings Call Insights
- Significant Revenue Growth: Repligen reported $194 million in revenue for Q1, reflecting a 15% year-over-year increase with 11% organic growth, indicating strong performance in the biopharmaceutical market that is expected to enhance future market share.
- Earnings Guidance Raised: The management has increased the full-year adjusted earnings per share guidance to between $1.97 and $2.05, reflecting confidence in the company's profitability while indicating that the divestiture of low-margin operations will improve overall financial health.
- Expansion in China: The company signed a critical OEM partnership to begin local manufacturing in China in 2027, which will not only enhance its presence in the Chinese market but also lay the groundwork for future revenue growth.
- Transformation Office Established: Repligen has formed a transformation office aimed at achieving a 30% adjusted EBITDA margin by 2030, with an expected annualized margin benefit of at least 1 percentage point by the end of 2027, demonstrating the company's commitment to long-term profitability.
See More
Repligen (RGEN) Q1 2026 Earnings Call Transcript
See More
Repligen Q1 Earnings Announcement Scheduled
- Earnings Release Date: Repligen (RGEN) is set to announce its Q1 earnings on May 5th before market open, with a consensus EPS estimate of $0.38, reflecting a 2.6% year-over-year decline, which may impact investor sentiment.
- Revenue Expectations: The expected revenue for Q1 is $192.17 million, representing a 13.7% year-over-year increase, indicating the company's growth potential in the market despite some pressure on profitability.
- Historical Performance: Over the past two years, Repligen has beaten EPS and revenue estimates 75% of the time, suggesting a level of stability and reliability in financial performance that may attract more investor interest.
- Estimate Revision Trends: In the last three months, EPS estimates have seen one upward revision and 13 downward revisions, while revenue estimates have experienced seven upward and six downward revisions, reflecting market divergence and uncertainty regarding the company's future performance.
See More
Repligen to Participate in William Blair Growth Stock Conference in Chicago
- Conference Participation: Repligen Corporation will participate in the 46th Annual Growth Stock Conference hosted by William Blair in Chicago on June 3, where CEO Olivier Loeillot will present a company overview at 10:40 a.m., showcasing its leadership in bioprocessing technology.
- Live Webcast: The presentation will be accessible via Repligen's Investor Relations website, with a replay available for a limited time post-event, ensuring that investors unable to attend can still access critical information.
- Company Background: Repligen is a global leader in life sciences focused on developing and commercializing innovative bioprocessing technologies that enhance the efficiency of biological drug manufacturing, serving biopharmaceutical developers and contract development manufacturing organizations worldwide.
- Global Presence: Headquartered in Waltham, Massachusetts, Repligen has its primary manufacturing sites in the U.S., with additional key facilities in Estonia, Germany, Ireland, the Netherlands, and Sweden, demonstrating its extensive influence in the global market.
See More
Repligen Releases 2025 Corporate Sustainability Report
- Renewable Energy Commitment: Repligen maintains 100% renewable electricity across its U.S. and European manufacturing operations, demonstrating a strong commitment to environmental sustainability that enhances its competitive position in the biopharmaceutical industry.
- Double Materiality Assessment: The company completed its first enterprise-level Double Materiality Assessment aligned with European Sustainability Reporting Standards (ESRS), which not only improved prioritization of material topics but also enhanced regulatory readiness, ensuring compliance with evolving regulations.
- Governance Structure Enhancement: By expanding sustainability oversight to the Audit Committee, Repligen has reinforced governance rigor and data integrity, ensuring alignment with stakeholder expectations, thereby increasing the company's transparency and trustworthiness.
- Water Resource Management Improvement: The company achieved a 14% year-over-year reduction in global water withdrawals, reflecting its commitment to environmental protection and establishing a positive corporate image in the sustainability arena.
See More
April PPI Report Triggers Decline in Healthcare Stocks
- PPI Acceleration Impact: The April PPI report showed a 6% annual increase, with service-sector prices rising at the fastest pace in four years, creating dual pressures on the healthcare sector, increasing operating costs and potentially impacting profitability.
- Cost Pressure: Monthly service-sector inflation rose by 1.2%, significantly increasing operating costs for hospital systems and providers, which may weaken their profitability and affect future investment decisions.
- Regulatory Intervention Risk: As inflation becomes a political focal point, drug companies, due to their visible pricing power, are primary targets for regulatory intervention, which could suppress industry profits.
- Market Overreaction: Despite healthcare stocks like Repligen and AdaptHealth falling by 3.2% and 3.6% respectively, the market's overreaction may present investors with good opportunities to buy high-quality stocks.
See More
Repligen Q1 2026 Earnings Call Insights
- Significant Revenue Growth: Repligen reported $194 million in revenue for Q1, reflecting a 15% year-over-year increase with 11% organic growth, indicating strong performance in the biopharmaceutical market that is expected to enhance future market share.
- Earnings Guidance Raised: The management has increased the full-year adjusted earnings per share guidance to between $1.97 and $2.05, reflecting confidence in the company's profitability while indicating that the divestiture of low-margin operations will improve overall financial health.
- Expansion in China: The company signed a critical OEM partnership to begin local manufacturing in China in 2027, which will not only enhance its presence in the Chinese market but also lay the groundwork for future revenue growth.
- Transformation Office Established: Repligen has formed a transformation office aimed at achieving a 30% adjusted EBITDA margin by 2030, with an expected annualized margin benefit of at least 1 percentage point by the end of 2027, demonstrating the company's commitment to long-term profitability.
See More
Repligen (RGEN) Q1 2026 Earnings Call Transcript
See More
Repligen Q1 Earnings Announcement Scheduled
- Earnings Release Date: Repligen (RGEN) is set to announce its Q1 earnings on May 5th before market open, with a consensus EPS estimate of $0.38, reflecting a 2.6% year-over-year decline, which may impact investor sentiment.
- Revenue Expectations: The expected revenue for Q1 is $192.17 million, representing a 13.7% year-over-year increase, indicating the company's growth potential in the market despite some pressure on profitability.
- Historical Performance: Over the past two years, Repligen has beaten EPS and revenue estimates 75% of the time, suggesting a level of stability and reliability in financial performance that may attract more investor interest.
- Estimate Revision Trends: In the last three months, EPS estimates have seen one upward revision and 13 downward revisions, while revenue estimates have experienced seven upward and six downward revisions, reflecting market divergence and uncertainty regarding the company's future performance.
See More
